RVL Pharmaceuticals plc to Present at Upcoming Conferences

RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at two significant conferences.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

RVL Pharmaceuticals plc (Nasdaq: RVLP) announced that CEO Brian Markison will present at two significant conferences. The H.C. Wainwright Global Investment Conference is scheduled for May 24, 2022, at 11:00 a.m. ET, in Miami Beach, FL, with a webcast available here. Another presentation will take place at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. ET, in New York City, NY, which can be accessed here.

Argus Session date unavailable

-2.76% session move Open Argus

Details

News Market Reaction – RVLP

The recorded move for RVLP in the trading session of this news was -2.76%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

05/16/2022 - 06:50 AM EDT

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

H.C. Wainwright Global Investment Conference, Miami Beach, FL
Date:	Tuesday, May 24, 2022
Time:	11:00 a.m. ET
Webcast:	Click Here

Jefferies Healthcare Conference, New York City, NY
Date:	Thursday, June 9, 2022
Time:	1:30 p.m. ET
Webcast:	Click Here

The webcasts will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Investor and Media Relations for RVL Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is RVLP presenting at the H.C. Wainwright Global Investment Conference?

RVLP will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 11:00 a.m. ET.

How can I watch RVLP's presentation at the Jefferies Healthcare Conference?

You can watch RVLP's presentation at the Jefferies Healthcare Conference on June 9, 2022, at 1:30 p.m. ET, via this link.

What is RVL Pharmaceuticals known for?

RVL Pharmaceuticals specializes in the commercialization of UPNEEQ, the first FDA-approved non-surgical treatment for acquired blepharoptosis.

Where can I find more information about RVLP's webcasts?

More information about RVLP’s webcasts can be found on their official website under the 'Investor & News' section.

Who is the CEO of RVL Pharmaceuticals?

The CEO of RVL Pharmaceuticals is Brian Markison.

Keep reading

RVL Pharmaceuticals plc to Present at Upcoming Conferences